QQQ   304.08 (+0.16%)
AAPL   152.41 (+0.45%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   99.76 (-2.37%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.72 (+0.05%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.87 (-2.71%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
QQQ   304.08 (+0.16%)
AAPL   152.41 (+0.45%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   99.76 (-2.37%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.72 (+0.05%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.87 (-2.71%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
QQQ   304.08 (+0.16%)
AAPL   152.41 (+0.45%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   99.76 (-2.37%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.72 (+0.05%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.87 (-2.71%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
QQQ   304.08 (+0.16%)
AAPL   152.41 (+0.45%)
MSFT   262.76 (+2.33%)
META   186.02 (-0.02%)
GOOGL   103.75 (+0.83%)
AMZN   99.76 (-2.37%)
TSLA   195.85 (+0.56%)
NVDA   212.85 (+0.93%)
NIO   10.90 (-0.27%)
BABA   105.89 (+0.42%)
AMD   83.72 (+0.05%)
T   19.45 (-0.66%)
F   13.11 (-0.23%)
MU   60.12 (+0.23%)
CGC   2.87 (-2.71%)
GE   81.57 (-0.95%)
DIS   109.70 (-0.15%)
AMC   6.64 (-2.35%)
PFE   43.85 (+0.21%)
PYPL   81.89 (-0.53%)
NFLX   357.85 (-1.00%)
NASDAQ:BLUE

bluebird bio - BLUE Stock Forecast, Price & News

$6.73
+0.07 (+1.05%)
(As of 02/7/2023 09:38 AM ET)
Add
Compare
Today's Range
$6.58
$6.74
50-Day Range
$5.92
$8.49
52-Week Range
$2.87
$8.58
Volume
69,354 shs
Average Volume
4.03 million shs
Market Capitalization
$558.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

bluebird bio MarketRank™ Forecast

Analyst Rating
Hold
1.89 Rating Score
Upside/​Downside
1.4% Upside
$6.75 Price Target
Short Interest
Bearish
22.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$62,595 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.39) to ($2.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.21 out of 5 stars

Medical Sector

998th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

166th out of 169 stocks

BLUE stock logo

About bluebird bio (NASDAQ:BLUE) Stock

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
bluebird bio: More Share Dilution Likely
Why are new drugs so expensive?
SVB Securities Reaffirms Their Hold Rating on Bluebird Bio (BLUE)
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Bluebird Bio Prices Public Offering Of 20 Mln Shares At $6.00/shr
BLUE bluebird bio, Inc.
Drug Prices Reach New High—in the Millions
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

BLUE Company Calendar

Last Earnings
11/05/2021
Today
2/07/2023
Next Earnings (Estimated)
3/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
518
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+0.3%
Consensus Rating
Hold
Rating Score (0-4)
1.89
Research Coverage
9 Analysts

Profitability

Net Income
$-819,380,000.00
Net Margins
-8,828.28%
Pretax Margin
-8,384.38%

Debt

Sales & Book Value

Annual Sales
$3.66 million
Book Value
$5.34 per share

Miscellaneous

Free Float
81,099,000
Market Cap
$558.05 million
Optionable
Optionable
Beta
0.92

Key Executives

  • Andrew ObenshainAndrew Obenshain
    President, Chief Executive Officer & Director
  • Thomas J. Klima
    Chief Operating & Commercial Officer
  • Christopher Stanley Krawtschuk
    Treasurer, Chief Financial & Accounting Officer
  • Richard Colvin
    Chief Medical Officer
  • Melissa Bonner
    Senior Vice President-Research













BLUE Stock - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price forecast for 2023?

9 analysts have issued 12 month price targets for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they expect the company's share price to reach $6.75 in the next year. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2023?

bluebird bio's stock was trading at $6.92 on January 1st, 2023. Since then, BLUE stock has decreased by 3.8% and is now trading at $6.66.
View the best growth stocks for 2023 here
.

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023.
View our BLUE earnings forecast
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing analysts' consensus estimates of ($2.65) by $0.51. The biotechnology company earned $22.70 million during the quarter, compared to analysts' expectations of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 173.58% and a negative net margin of 8,828.28%. The business's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the firm posted ($2.94) earnings per share.

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), Los Angeles Capital Management LLC (0.15%), Hennion & Walsh Asset Management Inc. (0.12%), Monaco Asset Management SAM (0.06%), Monaco Asset Management SAM (0.06%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends
.

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $6.66.

How much money does bluebird bio make?

bluebird bio (NASDAQ:BLUE) has a market capitalization of $552.25 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis.

How many employees does bluebird bio have?

The company employs 518 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.

This page (NASDAQ:BLUE) was last updated on 2/7/2023 by MarketBeat.com Staff